Watermark
  Back to Search Results

AdvanTIG-205

Completed

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

BeOne Study ID info

AdvanTIG-205

ClinicalTrials.gov ID info

NCT05014815

EudraCT Number info

2021-001075-17

China Drug Trials ID info

CTR20212782

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents